SOUTH SAN FRANCISCO, Calif.,
May 18, 2020 /PRNewswire/
-- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA)
today announced that, due to the public health impact of the
coronavirus (COVID-19) pandemic and to prioritize the health and
well-being of stockholders, employees and other meeting
participants, the location and format of its 2020 Annual
Stockholder Meeting (the "Annual Meeting") has been changed to a
virtual meeting. The virtual Annual Meeting is expected to provide
stockholders with the same rights and opportunities to participate
as they would have at an in-person meeting.
The Annual Meeting will be held on Friday, June 12, 2020, at 9:00 a.m. PT, as previously announced in the
Notice of the Annual Meeting and Definitive Proxy Statement.
Stockholders will not be able to attend the Annual Meeting in
person; however, stockholders as of the close of business on
April 17, 2020, (the "Record Date")
will be able to participate in the virtual Annual Meeting, vote
their shares and ask questions through an online meeting
platform.
Additional information for stockholders on how to
participate:
- To access the meeting platform, please visit:
https://web.lumiagm.com/283341663 beginning at 8:45 a.m. PT on Friday, June 12, 2020.
- In order to attend, vote and ask questions at the Annual
Meeting, stockholders must use an 11-digit voter control number and
password of ptla2020 to access the virtual meeting.
- Stockholders of record can find their 11-digit voter control
number on the proxy card or Notice of Internet Availability of
Proxy Materials previously received.
- Beneficial stockholders who hold their shares through a bank,
broker or other nominee must contact their bank, broker or other
nominee to request a Legal Proxy and present their Legal Proxy to
American Stock Transfer & Trust to obtain an 11-digit voter
control number. Requests for registration should be directed to
proxy@astfinancial.com or to facsimile number 718-765-8730. Written
requests can be mailed to:
American Stock Transfer & Trust Company LLC
Attn: Proxy Tabulation Department
6201 15th Avenue
Brooklyn, NY 11219
Requests for registration must be labeled as "Legal Proxy" and
be received no later than 5:00 p.m.
ET on June 2, 2020.
Voting Shares
Stockholders of record and beneficial owners will be able to
vote their shares electronically during the Annual Meeting.
Whether or not they plan to attend the Annual Meeting, all
stockholders as of the Record Date may vote in advance of the
meeting until 11:59 p.m. ET on
June 11, 2020, at www.voteproxy.com
or by using one of the other methods described in the proxy
materials for the Annual Meeting filed with the Securities and
Exchange Commission (the "SEC") on April 20,
2020. Stockholders who have already voted prior to the
Annual Meeting, and who do not wish to change their vote, do not
need to vote again during the Annual Meeting.
The proxy materials, including the proxy card and Notice of
Internet Availability of Proxy Materials, previously distributed
along with the Definitive Proxy Statement will not be updated to
reflect the change in the meeting location and may continue to be
used to vote shares in connection with the Annual Meeting.
Information regarding this change to the location and format of
the Annual Meeting can be found in the supplemental proxy materials
filed by Portola Pharmaceuticals with the SEC on May 18, 2020.
List of Stockholders
A list of stockholders entitled to vote at the Annual Meeting
will be available for examination for any purpose germane to the
Annual Meeting during normal business hours for 10 days prior to
the Annual Meeting at Portola Pharmaceuticals' corporate
headquarters. To the extent office access is impracticable due to
the coronavirus (COVID-19) pandemic, stockholders may email the
company at IR@portola.com for alternative arrangements. The
stockholder list will also be available electronically for
examination during the Annual Meeting.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a global, commercial-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapeutics that could significantly
advance the fields of thrombosis and other hematologic conditions.
The Company's first two commercialized products are
Andexxa® [coagulation factor Xa (recombinant),
inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet
alfa), and Bevyxxa® (betrixaban). The company also is
advancing cerdulatinib, a SYK/JAK inhibitor being developed for the
treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/portola-pharmaceuticals-announces-virtual-2020-annual-stockholder-meeting-301061109.html
SOURCE Portola Pharmaceuticals, Inc.®